Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended March 31, 2026, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Company.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Wockhardt Limited has filed its QIP Monitoring Agency Report for Q4 FY2026, issued by CRISIL Ratings Limited. The company raised Rs 1,000 crore gross (Rs 977.79 crore net) through a Qualified Institutions Placement in November 2024. Of this, Rs 815.46 crore (83%) has been utilized as of March 31, 2026, with Rs 162.33 crore remaining unutilized. The full Rs 500 crore allocated for debt repayment and Rs 227.79 crore for general corporate purposes have been fully deployed. However, only Rs 87.67 crore (35%) of the Rs 250 crore R&D and capital expenditure fund has been used, with the Board extending the utilization deadline to March 2028 due to ongoing project timelines. The unutilized funds are deployed in HDFC Mutual Fund (Rs 50 crore), Tata Mutual Fund (Rs 110.89 crore), and cash accounts (Rs 1.44 crore).
No deviation in fund utilization was reported, which is positive for shareholder confidence. The extension of R&D spending timeline suggests the company is taking a measured approach to capital deployment amid business considerations. The heavy deployment in debt repayment (100%) strengthens the balance sheet.